title: Laryngeal carcinoma prognosis after postoperative radiotherapy correlates with CD105 expression, but not with angiogenin or EGFR expression.
abstract: Patients with head and neck squamous cell carcinoma (SCC) respond very differently to radiotherapy (RT). Since clinical factors cannot accurately predict its effects, biological parameters have been investigated, including tumor hypoxia. CD105 is a hypoxia-inducible glycoprotein emerging as a potential prognostic indicator for several solid malignancies. Angiogenin is upregulated under hypoxic conditions and supports primary and metastatic tumor growth. Epidermal growth factor receptor (EGFR) activation stimulates tumor proliferation and angiogenesis. The aim of the present study was to ascertain the prognostic importance of hypoxia-inducible factors (CD105, angiogenin) and EGFR in a series of patients who underwent primary surgery followed by RT for laryngeal SCC. 25 consecutive patients with laryngeal SCC given postoperative RT have been investigated. CD105, angiogenin, and EGFR immunohistochemical expressions in primary laryngeal SCCs have been evaluated also with image analysis. The recurrence rate was significantly higher in SCC patients with a CD105 expression >10.0% (P = 0.012) and their disease-free survival (DFS) was shorter (P = 0.044). Neither angiogenin (in the carcinoma cells or endothelial cells) nor EGFR expression were associated with the prognosis in our patients after primary surgery followed by RT for laryngeal SCC. CD105 should be studied as a potentially predictive biomarker for identifying laryngeal SCCs at higher risk of early recurrence after postoperative RT. Targeted anti-CD105 therapy associated with RT should also be investigated in patients with laryngeal SCCs characterized by high CD105 expression.
authors.affiliation: Otolaryngology Section, Department of Medical and Surgical Specialties, University of Padova, Via Giustiniani 2, Padua, Italy. gino.marioni@unipd.it
authors.forename: Gino
authors.initials: G
authors.lastname: Marioni
authors.forename: Stella
authors.initials: S
authors.lastname: Blandamura
authors.forename: Lucio
authors.initials: L
authors.lastname: Loreggian
authors.forename: Haralabos
authors.initials: H
authors.lastname: Koussis
authors.forename: Marco
authors.initials: M
authors.lastname: Lionello
authors.forename: Luciano
authors.initials: L
authors.lastname: Giacomelli
authors.forename: Elena
authors.initials: E
authors.lastname: Fasanaro
authors.forename: Andrea
authors.initials: A
authors.lastname: Lovato
authors.forename: Alberto
authors.initials: A
authors.lastname: Staffieri
mesh_terms: D000368:Aged; D015703:Antigens, CD / Q000096:biosynthesis*; D014408:Biomarkers, Tumor / Q000096:biosynthesis; D002294:Carcinoma, Squamous Cell / Q000378:metabolism / Q000401:mortality* / Q000532:radiotherapy / Q000601:surgery; D018572:Disease-Free Survival; D000071063:Endoglin; D066246:ErbB Receptors / Q000096:biosynthesis*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007150:Immunohistochemistry; D007558:Italy / Q000453:epidemiology; D007822:Laryngeal Neoplasms / Q000378:metabolism / Q000401:mortality* / Q000532:radiotherapy / Q000601:surgery; D007825:Laryngectomy; D008297:Male; D009367:Neoplasm Staging; D011184:Postoperative Period; D011379:Prognosis; D011956:Receptors, Cell Surface / Q000096:biosynthesis*; D012189:Retrospective Studies; D012259:Ribonuclease, Pancreatic / Q000096:biosynthesis*; D015996:Survival Rate / Q000639:trends
chemical_list: D015703:Antigens, CD; D014408:Biomarkers, Tumor; C064206:ENG protein, human; D000071063:Endoglin; D011956:Receptors, Cell Surface; D066246:ErbB Receptors; C046366:angiogenin; D012259:Ribonuclease, Pancreatic